Oncology

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed recent and ongoing studies that are upending the paradigm in LBCL care.

The assistant professor of medicine at University of Alabama – Birmingham discussed efficacy findings on BMS-986983 and more research to be done.

The director of University of Washington Medicine’s Cancer Vaccine institute discussed the importance of continuing to develop new CAR-T approaches in the ovarian cancer field despite initial setbacks.

The BASECAMP-1 clinical trial will aim to find patients with advanced solid tumors who are good candidates for the subsequent EVEREST trial.

Two of 6 patients in the WM cohort achieved a complete response and 16 of 20 patients in the FL cohort achieved a complete response.

Review top news and interview highlights from the week ending June 16, 2023.

The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed potential methods for optimizing CAR-T efficacy that could be explored in the future.

The phase 1/2 Euplagia-1 trial is currently ongoing in Europe.

The assistant professor of medicine at University of Alabama – Birmingham discussed new data from the first-in-human trial of the CAR T-cell therapy.

New data from 3 patients were published in the New England Journal of Medicine.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed the safety and efficacy results he presented at EHA’s 2023 congress.

Seattle Children’s and 2seventy bio, which are collaborating on the development of SC-DARIC33, are currently investigating the cause of the grade 5 serious adverse event.

The associate professor at Medical College of Wisconsin discussed new findings from the CARTITUDE-4 study.

The objective response rate among patients treated at DL2 and DL3 who were evaluable for efficacy was 57%.

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.

Among 101 patients included in the efficacy analysis, the ORR was 96% and the CR rate was 74.3%.

The director of University of Washington Medicine’s Cancer Vaccine institute discussed results from a phase 1 study presented at ASCO’s 2023 conference.

Review top news and interview highlights from the week ending June 9, 2023.

The most recent data from CARTITUDE-4 were presented at the 2023 ASCO Meeting.

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed the real-world data she is presenting at EHA’s 2023 congress.

Updated data were presented at the ISCT 2023 Meeting.

The associate professor at Medical College of Wisconsin discussed the rationale for the CARTITUDE-4 study and its latest updates.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The study has enrolled 17 patients as of May 2023 and enrollment is expected to complete by the end of 2024.

New overall survival analysis data on Yescarta from ZUMA-7 were presented at the ASCO 2023 meeting.

The associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.

The professor of medicine and pediatrics at Washington University in St. Louis discussed evaluating afami-cel in the SPEARHEAD-1 trial.

Among 19 patients with r/r B-ALL included in the analysis, all 19 achieved a CR or CRi.

Safety findings were also improved when compared with the previous CARTITUDE-1 study, suggesting the therapy may be better tolerated in earlier lines of therapy.